Chronic kidney disease Flashcards
CKD - Definiation
eGFR <30 for >3months
AND/OR
Evidence of renal damage
- Haematuria (urological causes eliminated)
- Albuminuria
- Structural abnormality on imaging
- Pathological abnormality on biopsy
CKD - Causes
Diabetes (38%) Hypertension (12%) Polycystic kidney disease (7%) Glomerularnephritis (17%) Other (26%)
CKD risk factors and recommended screening
Screen - request
- eGFR
- Urine ACR
- BP
Diabetes, HTN -> screen annually
CVD, BMI >30, Family hx CKD, smokers -> screen 2nd yearly
-ATSI - age 18-29 - screen for risk factors regularly
-ATSI - age >30 - screen 2nd yearly
Other risk factors - no recommendation for screening
- Age >60
- Hx of HTN in pregnancy
- Hx of AKI
CKD screening process and diagnosis
- eGFR < 60
- Repeat in 7 days.
- If deterioration >20% - AKI - d/w renal
- If stable - repeat again - three samples over three months
Urine ACR
- Elevated - W - >3.5, M >2.5
- Repeat twice over three months
- Diagnosis
-3 reduced eGFR over 3+ month
AND / OR
-2+/3 Urine ACR elevated over 3+ months.
CKD Investigations
Everyone
- eGFR
- Urine ACR
-U&E (-CMP - my idea, not in the guidelines) -FBC (?Aneamia) -Fasting lipids -Fasting glucose -ESR, CRP
If systemic disease
- Connective tissue disorders
- Rashes / arthritis
- Pulmonary Sx
- Rapidly deteriorating renal function
-ANA, ENA, ANCA, Complement studies, Anti-glomerular basement membrane antibodies
If >40 yo and ?Myeloma (Ca++ elevated, particularly if >60)
-Serum and urine protein electrophoresis (looking for paraproteins)
If risk factors for HIV, HBV, HCV - serology
CKD management group definitions - Yellow
Stage IIIa - eGFR 45-59
OR
Stage I, II - eGFR >60 + microalbuminuria (F 3.5-35, M 2.5 -25)
CKD management group definition - Orange
Stage IIIb - eGFR 30-44
OR
Stage IIIa (eGFR 45-59 or b 30-44) + microalbuminuria (F 3.5-35, M 2.5-25)
CKD management group definition - Red
Stage IV, eGFR 15-29 OR V - eGFR <15 or needing dialysis
OR
Macroalbuminuria regardless of eGFR
- F >35
- M >25
CKD - review intervals per colour
Yellow - 12 monthly
Orange - 3-6 monthly
Red - 1-2 monthly
CKD - clinical assessment at review (4)
- Blood pressure (target <130-80)
- BMI and waist cirumference
- Smoking status
- Oedema (red only)
CKD Investigations - All colours (5)
eGFR Urine ACR U&E Fasting lipids HbA1c if diabetic or needing screening
CKD investigations - Orange and Red (4)
FBC - Hb target 100-115
U&E - K+ target
CKD investigations PRN
Albumin - target >35 - screen if ?malnutirion
Iron, B12, folate
TSH
CKD - assessment
- CVD risk
- Hypertension mgt
- Hyperlipidiaemia mgt
- Consider anti-platelet (orange and red) - Diabetes risk / control
- Medication review
- Dose adjustment / cessation as required - Lifestyle modification
- Basic - smoking, alcohol, exercise, weight, diet
- Diet for anti-hypertension - low salt <6g, high veggies
- > Protein >7.5mg/kg/day
- > Low K+ if a problem - Assess for common problems (16)
- Assess if needs renal input
- eGFR <30 or persistent Urine ACR >30
- Sustained decline in eGFR >25% or 15mL in 12 months
- HTN not controlled by three drugs
CKD - Common problems - 18
Everyone need to monitor
- Increased CVD risk
- HTN
- Hyperlipidaemia
- Albuminiuria
Consider
- Haematuria
- Anaemia
- Hyperkalaemia
- Low Ca++, high PTH
- Osteoporosis
- Ureamia
- Oedema
- Sleep apnoea
- Restless leg
- Muscle cramps
- Pruritis
- Malnutrition
- Depression
- Cognitive decline